Vincere Biosciences Inc
June 19, 2025
Company Presentation
Brain Health
153B
Vincere Biosciences is a precision medicine company advancing small molecule therapeutics that enhance mitophagy, a fundamental cellular repair process with the potential to reverse neurodegeneration and age-related decline. Our lead program, VB-23, is a first-in-class USP30 inhibitor entering IND-enabling studies for Parkinson’s disease, supported by strong PK, brain exposure, and mechanistic alignment with genetic drivers of mitochondrial dysfunction. Backed by Draper Associates, Beiersdorf, and other top-tier investors, Vincere’s AI-enabled discovery platform has also generated promising candidates for kidney and cardiometabolic indications. We combine computational insights with rational drug design to move fast from target to clinic, building a pipeline of mitochondrial therapeutics to restore health at its source.
Company HQ City:
Cambridge
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
VB-23 - Oral USP30 inhibitor for Parkinson's Disease
CEO
Spring Behrouz, PhD
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
IND/First in Human
What is your next catalyst (value inflection) update?
June 2026
Website
https://vincerebio.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}